vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon
August 03 2017 - 8:30AM
Business Wire
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the
U.S. Patent and Trademark Office has issued a patent with claims
protecting methods of treatment using azeliragon, the Company’s
oral antagonist of the Receptor for Advanced Glycation Endproducts
(RAGE) for treatment of mild Alzheimer’s disease. The patent number
is 9,717,710 (‘710 Patent).
The ‘710 Patent, expiring in October 2034, includes claims
covering methods of treating patients with mild Alzheimer’s disease
by administering about 5 mg per day of azeliragon. vTv expects that
the ‘710 Patent will be Orange Book listable. The ‘710 Patent adds
to the portfolio of US patents covering azeliragon, including a
composition of matter patent that is expected to expire in 2029.
vTv continues to prosecute additional patent applications to
further enhance its existing patent portfolio covering
azeliragon.
“vTv is currently the only company developing a treatment for
Alzheimer’s disease by targeting the RAGE receptor, which has
demonstrated potential in addressing three key pathologies in
Alzheimer's disease: amyloid-β, tau and chronic inflammation,” said
Steve Holcombe, president and CEO of vTv Therapeutics. “This new
patent is an important milestone as vTv prepares for the results of
our upcoming Phase 3 data readout.”
Azeliragon is currently being studied in a randomized,
double-blind, placebo-controlled Phase 3 trial investigating the
efficacy of azeliragon as a potential treatment to slow the decline
in cognition and functional activities for patients with mild
Alzheimer’s disease. Data from Part A of the trial is expected
to read out in late March 2018, data from Part B data is expected
to read out in late December 2018.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
The Company’s lead drug candidates were discovered with its
high-throughput drug discovery platform, TTP Translational
Technology®, which translates the functional modulation of human
proteins into safe and effective medicines. For further company
information, visit www.vtvtherapeutics.com.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These forward-looking
statements reflect our views with respect to future events as of
the date of this release and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170803005121/en/
InvestorsvTv Therapeutics Inc.Michael Gibralter,
646-378-2938IR@vtvtherapeutics.comorMediaPure Communications
Inc.Katie Engleman, 910-509-3977Katie@purecommunications.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024